A0623 Effects of empagliflozin on day-to-day variability of home blood pressure and heart rate in patients with type 2 diabetes

Abstract

Objectives: The effects of empagliflozin in addition to standard care, on day-to-day variability of self-measured home blood pressure (BP) and heart rate (HR) at home in patients with type 2 diabetes (T2DM) at high cardiovascular risk are not known. Methods: We followed twenty-three consecutive T2DM patients (mean age: 69 years old, 12 men, mean BMI: 29.0 kg/m2) with cardiovascular risk to add 10 mg of empagliflozin once daily for three months. Home BP and HR were measured once every morning at home, using an oscillometric device. Results: For home BP, empagliflozin significantly reduced systolic blood pressure (SBP) from 130 ± 11 mmHg at baseline to 126 ± 11 mmHg at the first week (1W) of the administration (P < 0.05). SBP achieved the target home BP goal (125 ± 11 mmHg) at the second week (2W) and was maintained during the study (12W: 124 ± 10 mmHg, P < 0.01). As regards day-to-day variability of SBP, SD mmHg and coefficient of variation (CV) %: SD/mean SBP decreased from 7.3 ± 3.5 mmHg and 5.6 ± 2.7 % at baseline to 6.7 ± 2.5 mmHg and 5.4 ± 1.9 %, respectively, at 1W (8W: 5.2 ± 2.3 mmHg and 4.2 ± 1.9 %, P < 0.05). In diastolic blood pressure (DBP), there was a significant reduction of SD and CV compared with that at baseline (4.9 ± 1.6 mmHg and 6.9 ± 2.3 % at baseline, 8W: 3.9 ± 1.8 mmHg and 5.5 ± 2% P < 0.05); however, there was no change of DPB (71 ± 10 mmHg at baseline). Similarly, there was a decreasing trend in SD and CV of HR (3.9 ± 1.2 beats per minute (bpm) and 6.3 ± 1.9 % at baseline, 4W: 3.3 ± 1.3 bpm and 5.4 ± 2.1 % p < 0.1), although there was no significant change in HR (62 ± 13 bpm at baseline). Conclusion: 1, Empagliflozin significantly reduced systolic home BP, without increasing HR in T2DM patients. 2, Empagliflozin tended to reduce the day-to-day variability of self-measured morning home BP and HR in T2DM patients.